Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Applied Physiology of Oxygen Toxicity: Mechanisms in Humans
NCT05761756Recruiting
- Sponsor
- Duke University
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of caffeine, methylphenidate hydrochloride extended-release chewable tablet and sodium bicarbonate in oxygen toxicity, hypercapnia and epilepsy (4 arms), sponsored by Duke University. Primary endpoint: Hypercapnic ventilatory response at 3 months. Started Nov 2023; status: recruiting.
02
Drugs
caffeinemethylphenidate hydrochloride extended-release chewable tabletsodium bicarbonate
03
Conditions
oxygen toxicityhypercapniaepilepsy
Beyond the preview
Go deeper on NCT05761756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761756.